Table 3.
Comparison of clinically relevant parameters between the initial curative treatment and the initial TACE groups
| Curative treatment (N = 71) | TACE (N = 97) | p value | |
|---|---|---|---|
| Child-Pugh scorea | |||
| A5 | 66 | 85 | 0.31b |
| A6 | 4 | 9 | |
| B7 | 1 | 3 | |
| HBs Aga | |||
| Negative | 16 (23%) | 44 (45%) | 0.003b |
| Positive | 54 (77%) | 53 (55%) | |
| Unknown | 1 | ||
| Anti-HCVa | |||
| Negative | 56 (84%) | 67 (69%) | 0.044b |
| Positive | 11 (16%) | 30 (31%) | |
| Unknown | 4 | ||
| Tumor size, cm | 2.5±0.9 | 2.8±0.9 | 0.028c |
| Total bilirubin | 0.69±0.28 | 0.82±0.36 | 0.032c |
| Albumin | 4.4±0.4 | 4.1±0.4 | <0.0001c |
| Prothrombin time | 10.9±0.6 | 11.3±0.8 | 0.0001c |
| Platelet (×10−3) | 184±58 | 138±58 | <0.0001c |
| FIB-4 | 1.8±1.0 | 4.0±3.0 | <0.0001c |
| AFP | 576±1,378 | 852±2,748 | 0.121c |
| AST | 37±20 | 50±34 | 0.001c |
| ALT | 48±28 | 54±40 | 0.710c |
TACE, transcatheter arterial chemoembolization; AFP, alpha-fetoprotein; FIB-4, Fibrosis-4.
a
The numbers for Child-Pugh score, HBs Ag, and Anti-HCV were numbers of patients.
b
Compared by Fisher's exact test.
c
Compared by the Wilcoxon rank-sum test.